Five-Year Breeding Data, Immunology, and Tumor Take Rates of an NMRI Nude Mouse Colony

Spruβ, Thilo; Schlemmer, Richard; Bernhardt, Günther; Wiesenmeyer, Franz; Baumann, Oskar

doi:10.1159/000425219

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Solid tumors developed within 8 weeks. For serial passage, the tumors were cut into 2-mm 3 pieces and transplanted subcutaneously into the thoracic region with a trocar (30).…”

Section: Introductionmentioning

confidence: 99%

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

Fellner¹,

Bauer²,

Miller³

et al. 2002

J. Clin. Invest.

Self Cite

View full text Add to dashboard Cite

“…Solid tumors developed within 8 weeks. For serial passage, the tumors were cut into 2-mm 3 pieces and transplanted subcutaneously into the thoracic region with a trocar (30).…”

Section: Introductionmentioning

confidence: 99%

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

Fellner¹,

Bauer²,

Miller³

et al. 2002

J. Clin. Invest.

Self Cite

View full text Add to dashboard Cite

“…Pharmacokinetic studies in nude mice. NMRI nu/nu mice were bred under specified pathogen-free conditions at 26°C, 70% relative humidity, and a 12-hour light/12hour dark cycle at the University of Regensburg (30). They were fed ad libitum with a breeding/maintenance diet (Altromin GmbH, Lage, Germany) and water containing 1.3 g/l potassium sorbate and 2 g/l chloramphenicol; pH was adjusted to 2.5 with HCl.…”

mentioning

confidence: 99%

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

Fellner¹,

Bauer²,

Miller³

et al. 2002

J. Clin. Invest.

Self Cite

309

View full text Add to dashboard Cite

Introduction Paclitaxel (Taxol) and derivatives are active against various tumors (1-6) and have also been used to treat malignant glioma and brain metastases (7-9). However, brain tumors constitute a difficult problem and the therapeutic benefit of paclitaxel has been variable and low. This could be attributed to its limited entry into the CNS. Although paclitaxel is very lipophilic, concentrations in the CNS are very low after intravenous administration (10, 11). Paclitaxel appears to be a substrate of the multidrug resistance protein p-gp (12-14), and it is likely that this transporter contributes to its limited access to the brain. P-gp is expressed in high levels in cultured brain capillary endothelial cells and in intact brain capillaries (15, 16). It is localized at the luminal surface of the endothelium (17, 18), and therefore is in the correct location to restrict permeation of a variety of drugs into the CNS (19-21). Animals with reduced p-gp function show an accumulation of p-gp substrates in the brain as well as a markedly increased sensitivity to neurotoxic p-gp substrates, e.g., ivermectin (18, 22, 23). The present study identifies in vitro a mechanism that limits paclitaxel access to the CNS and outlines a strategy to circumvent it by blocking p-gp. We demonstrated that the p-gp blocker valspodar enhances paclitaxel entry into the brains of mice after intravenous dosing and that valspodar dramatically increases paclitaxel effectiveness against a human glioblastoma implanted into the CNS of nude mice. These are the first data directly demonstrating the role of p-gp in limiting the therapeutic availability of paclitaxel to the CNS. Methods Chemicals. Valspodar (SDZ PSC 833) and the fluorescent cyclosporin derivative NBDL-CS were from Novartis Pharma GmbH

show abstract

“…Since usually more than 105 cells are required for establishing subcutaneous tumors in nude mice, tumorigenicity was not tested with cells directly isolated from shed blood, but with two cell lines derived from shed blood. After cell passage and clonai expansion, IO5 or 106 cells were injected subcuta¬ neously into the right flank of triplets of outbred NMRI nu/nu mice 22. …”

mentioning

confidence: 99%

Tumor Cells in Blood Shed From the Surgical Field

Hansen

Wolff²,

Knuechel³

et al. 1995

Arch Surg

258

150

View full text Add to dashboard Cite

Malignant cells identified regularly in the blood shed during tumor surgery and different from circulating tumor cells are of concern, since at the surgical site they may cause local tumor recurrence, or in the salvaged blood they may cause hematogenic metastasis after retransfusion. Therefore, the contraindication of intraoperative autotransfusion in tumor surgery is strongly supported, and a review of surgical procedures and adjuvant therapy may be indicated, as the passage of the identified cells to the shed blood is yet unknown.

show abstract

Five-Year Breeding Data, Immunology, and Tumor Take Rates of an NMRI Nude Mouse Colony

Cited by 4 publications

References 0 publications

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo

Tumor Cells in Blood Shed From the Surgical Field

Contact Info

Product

Resources

About